Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Squarex, LLC
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age ≥18
You may not be if
Self report having four or more episodes of herpes labialis in the past 12 months
People that have had treatment with anti viral therapy within 2 weeks before sensitization dose.
Pregnant or lactating females.
Current or recurrent non-herpetic infection or any underlying condition that may predispose to infection or anyone who has been admitted to the hospital due to bacteremia, pneumonia or any other serious infection.
Therapy with glucocorticoid or immunosuppressants at time of recruitment or within past 4 weeks, except for inhaled corticosteroids for asthma or topical steroids in sites other than face.
History of malignancy (except patients with surgically cured basal cell or squamous cell skin cancers)
History of organ transplantation
HIV-positive status determined by history at screening or known history of any other immunosuppressive disease.
Severe co-morbidities (diabetes mellitus requiring insulin, CHF (EF\<50% at baseline will be exclusionary) MI, CVA or TIA within 3 months of screening visit, unstable angina pectoris, oxygen-dependent severe pulmonary disease
History of exposure to squaric acid or squaric acid dibutyl ester.
Known hypersensitivity to DMSO
Any condition judged by the investigator to cause this clinical trial to be detrimental to the patient.
Subject is currently enrolled in another investigational device or drug trial(s), or subject has received other investigational agent(s) within 28 days of baseline visit.
Previous or current participation in a clinical trial of SADBE to treat herpes labialis.
Clareo Health | Double-blind, Vehicle-controlled Study of the Efficacy and Safety of SADBE in Subjects With Recurrent Herpes Labialis
